IMUX Taps Genentech Executive Lundgren as New CEO Amid Phase 3 MS Trials
Immunic appoints Erik Lundgren as CEO to lead commercialization efforts for its late-stage multiple sclerosis therapy candidate. Immunic Inc (NASDAQ:IMUX, FRA:10VA) has appointed Erik Lundgren as chief executive officer, replacing Daniel Vitt, who will remain on the board